I have had a couple as well. It is less likely to occur if the dasatinib-based effusion is completely resolved before starting the bosutinib, although not always. One of the things to consider is whether the original effusion is gone. I have been referred a number of patients who have effusions on other TKIs, but when you examine carefully, the original DAS-based had never completely disappeared. As Jorge pointed out, pleural and/or pericardial effusions are not limited to the src based TKIs such as DAS or BOS. If you read the product monograph for IM, you will find it there as one of the side effects of the early studies in previously TKI-naïve patients and I have definitely seen it with NIL even in patients who have not seen DAS or BOS.
Good point
Jeff